Idelalisib Shows Efficacy in Relapsed CLL and LymphomaMedscapeThis trial showed that idelalisib used in combination with rituximab (Rituxan, Genentech/Roche) offered an option for patients with relapsed CLL who were unable to tolerate chemotherapy. The…
MedPage TodayRheuminations: 2013 Year in ReviewMedPage TodayHowever, by the end of 2013 we now have many comparator trials that show after failing an initial TNF inhibitor, there is equivalent or better efficacy when targeting different mechanisms with…
|
Pharmacyclics: Facts Behind $10B Market Cap
YCharts To date, first-line treatment has usually consisted of Roche’s (RHHBY) monoclonal antibody Rituxan (rituximab) – which is directed against the CD20 antigen found on B lymphocytes – combined with a multi-agent chemotherapy regimen, most often CHOP … |
Rheuminations: A Cautionary TaleMedPage TodayTwice weekly etanercept (Enbrel) was started, with no relief, and he subsequently was switched to adalimumab (Humira) and eventually to rituximab (Rituxan). Through the year of treatment with the biologics h…
|
$10B Market By 2022: Pharmacyclic’s Piece Of It
YCharts To date, first-line treatment has usually consisted of Roche’s monoclonal antibody Rituxan (rituximab) – which is directed against the CD20 antigen found on Beta lymphocytes – combined with a multi-agent chemotherapy regimen, most often CHOP … |
|
Forecasting Earnings Growth And Profitability In The Biopharmaceutical Industry
Seeking Alpha … had approval to market AVONEX® interferon beta-1a for multiple sclerosis, RITUXAN® rituximab for lymphoma and rheumatoid arthritis, TYSABRI® natalizumab for multiple sclerosis and Crohn’s disease, and FUMADERM® dimethylfumarate for psoriasis. |
|
This Week in Rheumatology: Gout and the ACR Winter Meeting
MedPage Today … week in rheumatology look for: Gout — it’s on the increase, with potentially serious consequences; B-cell depletion with rituximab shows promise in systemic sclerosis in a new study; The ACR Winter Rheumatology Symposium kicks off in Snowmass, Colo. |
Hematologists join cancer care allianceHealio… on the evolution of therapy-related acute myeloid leukemia. Head-to-head comparison of obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil in patients with chronic lymphocytic leukemia and co-…
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven …7thSpace Interactive (press release)Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin l…
Pharmacy group presents awardHealio… on the evolution of therapy-related acute myeloid leukemia. Head-to-head comparison of obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil in patients with chronic lymphocytic leukemia and co-existing m…